Recently, Shengnoki Pharmaceutical Company received investment of hundreds of millions of yuan from New Henglida Capital and several other institutions E rounds.

 

The biomedical sector is one of the three major investment directions of the new Henglida capital focus layout, in this field of new Henglida investment enterprises have two will soon land on the board, as well as a merger and acquisition exit. Under the cold winter of capital, New Henglida Capital continues to be favored by LP investors, continues to obtain financing, and frequently makes moves at the investment end. Recently, New Henglida Capital and several other brother institutions jointly contributed hundreds of millions of yuan to participate in Shengnuoji Pharmaceutical E-round financing.

 

Shengnuoji Pharmaceutical Company was established in Beijing in 2006. It is a biomedical enterprise focusing on the research and development and production of tumor and immune inflammatory drugs. It integrates innovative advantages such as new technologies, new targets, new products, and independent intellectual property rights. From small molecules, oncolytic viruses to immune checkpoint PD-L1 antibodies, etc., it has applied for more than 80 domestic and foreign invention patents, 39 of which have been authorized and have core competitiveness advantages, independent intellectual property rights are clear, is the leader of tumor immunotherapy drug research and development.

 

 

 

At present, the new natural class 1 drug, acoladine, which is independently developed by the company and comes from the traditional herb epimedium, is undergoing phase iii clinical trials, the new chemical class 1 drug is SNG-1153 approved to carry out clinical trials in China and the United States, and the ER-α36 antibody diagnostic reagent for class iii medical devices is undergoing clinical research; the joint development of oncolytic virus acoladine and PD-L1 acoladine will soon begin phase iii clinical trials, phase III clinical trials are SNG1005 to be conducted in the United States and China. On May 29, 2019, the Drug Evaluation Center of the State Medical Products Administration has approved Beijing Shengnuoji Pharmaceutical Technology Co., Ltd. to carry out "a chemical drug class 1 new drug injection SNG1005 for the treatment of HER2 after previous whole brain radiotherapy Multicenter, randomized controlled, open-label clinical trial in patients with brain metastases from negative breast cancer" (acceptance number: JXHL1900058).

 

 

At present, there is no standard treatment drug for brain metastasis of breast cancer. The existing treatment methods are whole brain radiotherapy or stereotactic radiotherapy, and the survival time of patients is very short, and the prognosis of HER2-negative population is worse. Due to the problem of the ability of drugs to penetrate the blood-brain barrier, most chemotherapy drugs are difficult to be enriched in the brain, and the efficacy is limited by systemic toxicity and the sensitivity of primary tumor chemotherapy. There are currently no approved drugs for the treatment of intracranial metastases. There is an urgent need for effective drugs to meet the strong desire for survival in patients with brain metastases such as breast cancer. Chemical drug class 1 new drug SNG1005 (also known as ANG1005) is the first class 1 new drug that can specifically deliver paclitaxel to the brain in China. SNG1005 is a conjugate formed by the combination of paclitaxel molecules and chemically synthesized amino acid polypeptides, which is a brand-new compound entity that has not been listed at home and abroad. The new drug can cross the blood-brain barrier (BBB) and blood-cerebrospinal fluid barrier (BCB) and enter the brain to play an anti-tumor effect. Two phase I clinical trials and four multi-center and open phase II clinical trials have been completed in the United States and Canada. Two phase II clinical trials of breast cancer with brain metastasis have been completed. SNG1005 has a clear clinical therapeutic effect on breast cancer brain metastasis and extracranial tumors, and its safety is similar to that of ordinary paclitaxel and has no serious allergic reaction. In July 2018, the US FDA agreed to carry out phase III clinical research on breast cancer brain metastasis in the United States, which is being fully promoted by Shengnuoji's partner, Angiochem Canada.

 

The company's core management team has rich experience in research and development of new drugs at home and abroad. The team has successively won the national "Eleventh Five-Year Major New Drug Creation", "Twelfth Five-Year Major New Drug Creation", "Innovation Fund", "2018 China's Top 50 Most Investment Valuable Enterprises", "2013 China Research Achievement Award", "Zhongguancun High-tech Enterprise", "Beijing International Science and Technology Cooperation Base" and other awards, won the strong support of many government funds, and attracted a large number of well-known venture capital companies to invest, promote the development and industrialization of original anti-cancer drugs. The company received capital injections from a number of investment companies, including Enlightenment Venture Capital, IDG Capital, Junlian Capital, Qiming Venture Capital, Pan Lin Capital, Shenzhen Venture Capital and Guoshou Shangxin.